GlassScriptPhysician profile
Natalie S Sohn
NPI 1194897561
$3,905.95
in general payments reported to CMS, 2019-2025
33 companies · $280 in 2025
The $280 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $710 · 2020: $135 · 2021: $778 · 2022: $599 · 2023: $777 · 2024: $627 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,567 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,567.43 |
| Education | $116.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $434.05 | 2023-2025 | Myfembree |
| Mayne Pharma Commercial LLC | $401.64 | 2022-2025 | |
| Myovant Sciences INC. | $398.85 | 2021-2022 | |
| Therapeuticsmd, INC. | $250.89 | 2019-2021 | |
| Exeltis, USA INC. | $249.86 | 2019-2024 | Slynd, Solosec |
| Abbvie INC. | $219.46 | 2020-2023 | Oriahnn, Lo Loestrin Fe, Orilissa |
| Astellas Pharma US INC | $198.80 | 2019-2024 | Veozah, Myrbetriq |
| Hologic Sales and Service, LLC | $173.14 | 2021-2025 | Novasure |
| Pfizer INC. | $169.10 | 2019-2023 | |
| Millicent US INC | $142.52 | 2019-2025 | Intrarosa, Femlyv, Femring |
| Lupin INC. | $120.67 | 2019-2021 | |
| Novo Nordisk INC | $116.77 | 2019-2024 | Wegovy |
| Kvk-Tech, INC. | $107.85 | 2019-2021 | |
| Cumberland Pharmaceuticals, INC. | $100.76 | 2019-2022 | |
| Exact Sciences Corporation | $78.62 | 2023-2024 | Cologuard Collection Kit |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $76.53 | 2019-2020 | |
| Radius Health, INC. | $73.79 | 2021-2022 | |
| Shield Therapeutics INC | $72.68 | 2023 | Accrufer |
| Duchesnay USA Incorporated | $61.79 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $57.16 | 2019-2022 | |
| Vertex Pharmaceuticals Incorporated | $56.75 | 2025 | |
| Organon LLC | $55.39 | 2022-2025 | Jada System |
| Avion Pharmaceuticals | $47.82 | 2019-2023 | Balcoltra |
| Agile Therapeutics, INC. | $38.94 | 2021-2022 | |
| Coopersurgical, INC. | $38.05 | 2024 | Summit Doppler |
| Amgen INC. | $28.88 | 2022 | |
| Merck Sharp & Dohme LLC | $27.37 | 2019-2023 | Gardasil 9 |
| Ethicon US, LLC | $23.26 | 2019 | |
| Lilly USA, LLC | $19.61 | 2025 | Mounjaro |
| Sage Therapeutics, LLC | $19.24 | 2021 | |
| Vivus LLC | $17.34 | 2022 | |
| Mylan Pharmaceuticals INC. | $15.89 | 2021 | |
| Vertical Pharmaceuticals, LLC | $12.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Sohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.